Regulation of gut microbiota in Alzheimer’s disease mice by silibinin and silymarin and their pharmacological implications
The newly reported associations between Alzheimer’s disease (AD) and gut microbiota indicate the potential of gut microbiota regulation–based therapeutic intervention for AD. Silymarin and its main active component, silibinin, are promising natural agents against AD, while their acting mechanisms remain to be explored. The present study investigated the effects of silibinin and silymarin administration on behavioral and histological manifestations, and regulation on the gut microbiota of transgenic APP/PS1 mice. First, silibinin and silymarin administration could alleviate memory deficits and reduce the amyloid plaque burden in the brain of APP/PS1 mice in comparison with controls. Second, silibinin and silymarin administration tended to decrease the microbiota diversity and exhibited regulative effect in abundances on several key bacterial species associated with AD development. This implied that gut microbiota regulation by silibinin and silymarin might be involved in their effects against AD. Further studies are warranted to fully elucidate the molecular mechanisms.
KeywordsAlzheimer’s disease Silymarin Silibinin Gut microbiota
HFJ and LS conceived and directed the study and drafted and revised the manuscript. LL, XYL, and LS performed the experiments and analyzed the data.
This work was supported by the Shandong Provincial Natural Science Foundation (Grant No. ZR2018MH010), Shandong Provincial Key Research and Development Program (Grant No. 2018GSF121001), National Science and Technology Major Projects of New Drugs (Grant No. 2015ZX09102015), and Talent Program of Zibo.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
- Jiang HH, Yan FS, Shen L, Ji HF (2016) Silymarin versus silibinin: differential antioxidant and neuroprotective effects against H2O2-induced oxidative stress in PC12 cells. Nat Prod Commun 11:633–636Google Scholar
- Lorenz D, Lücker PW, Mennicke WH, Wetzelsberger N (1984) Pharmacokinetic studies with silymarin in human serum and bile. Method Find Exp Clin 6:655–661Google Scholar
- Lu P, Mamiya T, Lu LL, Mouri A, Niwa M, Hiramatsu M, Zou LB, Nagai T, Ikejima T, Nabeshima T (2009a) Silibinin attenuates amyloid beta(25-35) peptide-induced memory impairments: implication of inducible nitric-oxide synthase and tumor necrosis factor-alpha in mice. J Pharmacol Exp Ther 331:319–326CrossRefGoogle Scholar
- Luper S (1998) A review of plants used in the treatment of liver diseases: part 1. Altern Med Rev 3:410–421Google Scholar
- World Alzheimer Report (2015) Available online: https://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf